Ilan Bruchim

5.5k citations

101 papers · 2.2k indexed · h-index 24

Impact in

Reproductive Medicine top 1%
- Ovarian cancer diagnosis and treatment
Obstetrics and Gynecology top 2%
- Endometrial and Cervical Cancer Treatments

Papers in

Reproductive Medicine 46
- Ovarian cancer diagnosis and treatment 43
- Endometriosis Research and Treatment 8
Obstetrics and Gynecology 34
- Endometrial and Cervical Cancer Treatments 32
- Uterine Myomas and Treatments 14

Co-authors: Haim Werner Ami Fishman Rive Sarfstein Walter H. Gotlieb Patrick Petignat Michaël Pollak Jing Gu Eduardo L. Franco
Journals: International Journal of Gynecological Cancer (11 papers)Gynecologic Oncology (11 papers)European Journal of Obstetrics & Gynecology and Reproductive Biology (6 papers)European Journal of Surgical Oncology (5 papers)Annals of Oncology (4 papers)
Partner nations: Israel Canada United States

In The Last Decade

Ilan Bruchim

92 papers receiving 2.1k citations

Peers

Countries citing papers authored by Ilan Bruchim

Since Specialization

Citations

This map shows the geographic impact of Ilan Bruchim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ilan Bruchim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ilan Bruchim more than expected).

Fields of papers citing papers by Ilan Bruchim

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ilan Bruchim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ilan Bruchim. The network helps show where Ilan Bruchim may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Ilan Bruchim, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Ilan Bruchim Line = papers co-authored together Ilan Bruchim links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	The MISOPRED score: Development and validation of a clinical scoring system to predict the effectiveness of Misoprostol treatment for early pregnancy loss PLoS ONE ·Sergio R. Franco, Javad Shokrizadeh, Oldemar Rodr, Alon Shrim, K. Getyengana, Raphy Zarecki, Mordechai Hallak, Ilan Bruchim	2024	0
2	IGF1R inhibition and PD-1 blockade improve anti-tumor immune response in epithelial ovarian cancer Frontiers in Oncology ·靖宏村上, D Bordević, Shay Hantisteanu, Sergio R. Franco, Давыдова Елена, Gabriel M. Groisman, Mordechai Hallak, Haim Werner, Ilan Bruchim	2024	0
3	LBA30 ATHENA-COMBO, a phase III, randomized trial comparing rucaparib (RUCA) + nivolumab (NIVO) combination therapy vs RUCA monotherapy as maintenance treatment in patients (pts) with newly diagnosed ovarian cancer (OC) Annals of Oncology ·Model Ordinanceschnical Staff, Amanda K. Marcon, David M. O’Malley, Γεώργιος Θ. Χρυσολωράς, Domenica Lorusso, Shannon N. Westin, Amit M. Oza, Perttu Immonen, Guo Hailian, Olga Mikheeva, Christine Parkinson, I.V. Makeev, Myong Cheol Lim, Anita Chudecka-Głaz, Ramez N. Eskander, Ilan Bruchim, Sharad Ghamande, Darrin Despain, Mayr Michel, Rebecca Kristeleit	2024	13
4	LBA37 Atezolizumab (atezo) combined with platinum-based chemotherapy (CT) and maintenance niraparib for recurrent ovarian cancer (rOC) with a platinum-free interval (TFIp) >6 months: Primary analysis of the double-blind placebo (pbo)-controlled ENGOT-Ov41/GEICO 69-O/ANITA phase III trial Annals of Oncology ·Dyane Brito, M.J. Rubio Pérez, Florian Heitz, R D Christensen, Nicoletta Colombo, Toon Van Gorp, Ana Oaknin, Alexandra Léary, (unknown), Coriolan Lebreton, Farish Hg, Margarita Romeo, Andrés Redondo, M.P. Barretina Ginesta, José Alejandro Pérez Fidalgo, Ana Santaballa Bertrán, 季娇, Ilan Bruchim, Marta Bahlai, Frédèric Selle	2023	6
5	#554 Is there a prognostic value for the positive lymph-node ratio? An israeli gynecologic oncology group study Zvi Vaknin, L. Asprea, Eero Ojanen, Limor Helpman, Ram Eitan, Ofer Lavie, Amnon Amit, Tally Levy, Inbar Ben Shachar, Ivan Sukharev-Krylov, Ilan Bruchim, Alon Ben Arie, Ofer Gemer	2023	0
6	Assessment of oncological safety and utility of hysteroscopy in high grade endometrial cancers: Results from an Israel gynecologic oncology group study European Journal of Obstetrics & Gynecology and Reproductive Biology ·Eero Ojanen, Limor Helpman, Ram Eitan, Zvi Vaknin, Ofer Lavie, Amnon Amit, Tally Levy, Inbar Ben Shachar, Ivan Sukharev-Krylov, Ilan Bruchim, Alon Ben Arie, Ofer Gemer	2023	2
7	Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapy European Journal of Cancer ·Thelma Carolina Bonilla Viera, Michael Friedländer, Sarah J. Lord, Rebecca Asher, Manuel Rodrigues, Jonathan A. Ledermann, Ursula A. Matulonis, Amit M. Oza, Ilan Bruchim, Tomasz Huzarski, Charlie Gourley, Philipp Harter, Ignace Vergote, Clare L. Scott, Werner Meier, Ronnie Shapira‐Frommer, Tsveta Milenkova, Éric Pujade-Lauraine, Val Gebski, Chee Khoon Lee	2021	9
8	Is the extent of pelvic lymphadenectomy in the staging of endometrial cancer associated with the yield of metastatic nodes? An Israeli Gynecologic Oncology Group study Surgical Oncology ·Misgav Rottenstreich, Ofer Gemer, Limor Helpman, Diana T. Trang, Ram Eitan, Oded Raban, Ofer Lavie, Alon Ben Arie, J. B. Arant, Tally Levy, Jeong-Min Yeon, Ammar A Ammar, Inbar Ben Shachar, Ivan Sukharev-Krylov, Ilan Bruchim, Zvi Vaknin	2020	1
9	Investigational IGF1R inhibitors in early stage clinical trials for cancer therapy Expert Opinion on Investigational Drugs ·Haim Werner, Rive Sarfstein, Ilan Bruchim	2019	48
10	Insulin-like Growth Factor 1 Signaling Axis Meets p53 Genome Protection Pathways Frontiers in Oncology ·Haim Werner, Rive Sarfstein, Derek LeRoith, Ilan Bruchim	2016	50
11	The IGF Hormonal Network in Endometrial Cancer: Functions, Regulation, and Targeting Approaches Frontiers in Endocrinology ·Ilan Bruchim, Rive Sarfstein, Haim Werner	2014	68
12	Targeting IGF-1 signaling pathways in gynecologic malignancies Expert Opinion on Therapeutic Targets ·Ilan Bruchim, Haim Werner	2013	54
13	Can parametrectomy be avoided in early cervical cancer? An algorithm for the identification of patients at low risk for parametrial involvement European Journal of Surgical Oncology ·Ofer Gemer, Ram Eitan, Michael Gdalevich, 服部晃幸, Benjamin Piura, Alex Rabinovich, Hanoch Levavi, A M Lin, R. Halperin, J. Siegrist, Uziel Beller, Ilan Bruchim, Tally Levy, Inbar Ben Shachar, Alon Ben Arie, Ofer Lavie	2012	39
14	Insulin-like growth factor-I receptor (IGF-IR) targeting with monoclonal antibody cixutumumab (IMC-A12) inhibits IGF-I action in endometrial cancer cells European Journal of Cancer ·Chaitanya Ghanta, Itay Bentov, Dale L. Ludwig, Ami Fishman, Ilan Bruchim, Haim Werner	2011	28
15	BRCA1/2 Germline Mutations in Jewish Patients With Uterine Serous Carcinoma International Journal of Gynecological Cancer ·Ilan Bruchim, Parker Grant, Dvora Kidron, María García-Gil, Tal Biron‐Shental, Liat Drucker, Eitan Friedman, Haim Werner, Ami Fishman	2010	39
16	Genetic alterations detected by comparative genomic hybridization and recurrence rate in epithelial ovarian carcinoma Cancer Genetics and Cytogenetics ·Ilan Bruchim, Ofir Israeli, Salaheddin M. Mahmud, Ayala Aviram‐Goldring, Shlomit Rienstein, Eitan Friedman, Gilad Ben‐Baruch, Walter H. Gotlieb	2009	9
17	Are self-collected samples comparable to physician-collected cervical specimens for human papillomavirus DNA testing? A systematic review and meta-analysis Gynecologic Oncology ·Patrick Petignat, Daniel Faltin, Ilan Bruchim, Martin R. Tramèr, Eduardo L. Franco, François Coutlée	2007	221
18	Doxorubicin levels in the serum and ascites of patients with ovarian cancer European Journal of Surgical Oncology ·Walter H. Gotlieb, Ilan Bruchim, Gilad Ben‐Baruch, Ben Davidson, Ellen van Holstein, Anders Andersen, Harald Olsen	2006	10
19	Insulin-like growth factor receptor I targeting in epithelial ovarian cancer Gynecologic Oncology ·Walter H. Gotlieb, Ilan Bruchim, Jing Gu, Ying Shi, Anne Camirand, Marie‐José Blouin, Yunhua Zhao, Michaël Pollak	2005	60
20	Postpartum chills phenomenon: Is it a feto‐maternal transfusion reaction? Acta Obstetricia Et Gynecologica Scandinavica ·Dorit Ravid, Yariv Gidoni, Ilan Bruchim, M. Severin, Moshe Fejgin	2001	7

About Ilan Bruchim

Ilan Bruchim is a scholar working on Reproductive Medicine, Obstetrics and Gynecology, Endocrinology, Diabetes and Metabolism, Oncology and Cancer Research, having authored 101 papers that have together received 2.2k indexed citations. Recurring topics across this work include Ovarian cancer diagnosis and treatment (43 papers), Endometrial and Cervical Cancer Treatments (32 papers), Growth Hormone and Insulin-like Growth Factors (22 papers), Uterine Myomas and Treatments (14 papers), Metabolism, Diabetes, and Cancer (12 papers), Cervical Cancer and HPV Research (12 papers), BRCA gene mutations in cancer (10 papers) and Endometriosis Research and Treatment (8 papers). The work is most often cited by research in Reproductive Medicine (498 citations), Obstetrics and Gynecology (393 citations), Cancer Research (463 citations), Oncology (646 citations) and Endocrinology, Diabetes and Metabolism (390 citations). Ilan Bruchim has collaborated with scholars based in Israel, Canada and United States. Frequent co-authors include Haim Werner, Ami Fishman, Rive Sarfstein, Walter H. Gotlieb, Patrick Petignat, Michaël Pollak, Jing Gu, Eduardo L. Franco, François Coutlée and Daniel Faltin. Their work appears in journals such as International Journal of Gynecological Cancer, Gynecologic Oncology, European Journal of Obstetrics & Gynecology and Reproductive Biology, European Journal of Surgical Oncology and Annals of Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact